Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its subsidiary Pearsanta Inc., have announced the acquisition of MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early-disease and cancer-detection platform. According to the announcement, the acquisition “reinforces Pearsanta’s dedication to enhancing patient outcomes through early-disease detection and the power of precision diagnostics.” The acquisition includes the pioneering Mitomic(TM) technology, which harnesses the unique attributes of mitochondrial DNA (“mtDNA”) to detect diseases at their earliest stages with precision and minimal invasiveness. Key components of the asset portfolio include the Mitomic Endometriosis Test (MET(TM)), which is in development as a blood-based assay for diagnosis of endometriosis; the Mitomic Prostate Test (MPT(TM)), also currently under development as a blood-based assay for diagnosis of prostate cancer; and a development pipeline including tests for various cancers such as ovarian, lung, pancreatic, liver, breast, stomach, esophageal and colorectal cancer. “Integrating these assets into our portfolio represents a significant milestone for Pearsanta,” said Pearsanta CEO Ernie Lee in the press release. “It could open a world of possibilities to harness the unique power of mitochondrial DNA in disease detection and precision medicine. We believe that mitochondrial DNA is an exceptional liquid biopsy technology, and our entry into this transaction underscores our dedication to pioneering innovations that can significantly impact global patient care. Adding this asset portfolio represents a major stride forward in our potential to empower individuals with the knowledge and tools they need to take control of their health. Our focus remains firmly on delivering innovative solutions that enhance healthcare accessibility and transform the lives of individuals.”
To view the full press release, visit https://ibn.fm/82tUh
About Aditxt Inc.
Aditxt is focused on discovering, developing and deploying promising health innovations. Aditxt’s diverse portfolio includes Adimune(TM) Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity and allergies; Adivir(TM) Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta(TM) Inc., offering timely, convenient and high-quality personalized lab testing anytime and anywhere, backed by its CLIA-certified and CAP-accredited monitoring center. For more information, please visit www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
